Momentus Inc. (MNTS): Nasdaq/NYSE listing notice — Momentus receives Nasdaq deficiency notice for delayed 2023 Form 10-K; deadline June 17, 2024

Momentus Inc.

Received Nasdaq deficiency notice on April 17, 2024, for failure to timely file 2023 Form 10-K (Listing Rule 5250(c)(1)).
No immediate impact on listing; 60 calendar days (until June 17, 2024) to file or submit a compliance plan to Nasdaq.
If plan accepted, Nasdaq may grant up to 180-day extension (to Oct 14, 2024) to regain compliance.
Failure to regain compliance could result in delisting; company intends to file 10-K as soon as financial review is complete.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Momentus Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: late filing
Rules: 5250(c)(1)

Exact text from the filing

April 17, 2024, Momentus Inc. (the “Company”) received a deficiency letter (the “Notice”) from the Nasdaq Capital Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the requirements of Nasdaq Listing Rule 5250(c)(1) as a result of not having timely filed with the U.S. Securities and Exchange Commission (the “Commission”) its Form 10-K for the year ended December 31, 2023 (the “Form 10-K”). The Notice has no immediate impact on the listing of the Company’s common stock on Nasdaq, and the Company’s listing remains fully effective. The Company has 60 calendar days fr

View on SEC.gov

94 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Momentus Inc. filing history →

Source: SEC EDGAR

accession 0001140361-24-020794

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.